Please use this identifier to cite or link to this item:
metadata.artigo.dc.title: Current approaches against Alzheimer's disease in clinical trials
metadata.artigo.dc.creator: Kuca, Kamil
Soukup, Ondrej
Maresova, Petra
Korabecny, Jan
Nepovimova, Eugenie
Klimova, Blanka
Honegr, Jan
Ramalho, Teodorico C.
França, Tanos C. C.
metadata.artigo.dc.subject: Alzheimer's disease - Treatment
Acetylcholinesterase inhibitors
Doença de Alzheimer - Tratamento
Inibidores da acetilcolinesterase
metadata.artigo.dc.publisher: Sociedade Brasileira de Química 2016
metadata.artigo.dc.identifier.citation: KUCA, K. et al. Current approaches against Alzheimer's disease in clinical trials. Journal of the Brazilian Chemical Society, São Paulo, v. 27, n. 4, p. 641-649, 2016.
metadata.artigo.dc.description.abstract: Alzheimer's disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Currently, this disease represents one of the uppermost human issues, both from the medical and economic point of view. Interest in the discovery of a drug for AD is enormous. However, despite the long-term and worldwide effort for a more effective therapy, the only available treatment is a symptomatic use of acetylcholinesterase inhibitors (AChEIs) and memantine. New therapeutic approaches as well as those based on cholinergic or amyloid theory have not brought the desired benefits yet. Thus, the question is whether an effective drug for this progressive disease will ever be developed or whether people will have to rely only on prevention and minimize risk factors of AD.
metadata.artigo.dc.language: en_US
Appears in Collections:DQI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_Current Approaches Against Alzheimer's Disease in Clinical Trials.pdf1,3 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons